Key facts
- This page summarizes Tamara A. Ranalli's Form 4 filing for QUIDEL CORP /DE/.
- 18 reported transactions and 17 derivative rows are listed below.
- Accepted by SEC: 01 Jun 2022, 16:29.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Disposed to Issuer
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Additional SEC filing notes
Section 16 status
Tamara A. Ranalli is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Footnote F1
Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.
Footnote F2
Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
Footnote F3
Vested in full.
Footnote F4
2,265 shares are vested in full; 755 shares will vest on February 4, 2023.
Footnote F5
1,186 shares are vested in full; the remaining 1,186 shares will vest in equal installments on February 3, 2023 and February 3, 2024.
Footnote F6
476 shares are vested in full; 476 shares will vest on August 24, 2022; the remaining 954 shares will vest in equal installments on August 24, 2023 and August 24, 2024.
Footnote F7
473 shares are vested in full; the remaining 1,419 shares will vest in equal installments on February 1, 2023, February 1, 2024 and February 1, 2025.
Footnote F8
1,239 shares will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025;1,240 shares will vest on January 31, 2026.
Footnote F9
Each restricted stock unit represents the right to receive one share of Quidel common stock.
Footnote F10
Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
Footnote F11
1,510 shares will vest on February 4, 2023.
Footnote F12
1,186 shares will vest in equal installments on February 3, 2023 and February 3, 2024.
Footnote F13
591 shares will vest in equal installments on August 24, 2022, August 24, 2023 and August 24, 2024.
Footnote F14
473 shares will vest on each of February 1, 2023 and February 1, 2024; 474 shares will vest on February 1, 2025.
Footnote F15
1,239 shares will vest on each of January 31, 2023 and January 31, 2024; 1,240 shares will vest on each of January 31, 2025 and January 31, 2026.
Footnote F16
1,693 shares will vest on January 31, 2024; 846 shares will vest on January 31, 2025; and 847 shares will vest on January 31, 2026.